Sally L. Hodder, MD

Associate Vice President for Clinical and Translational Science and Director

Organization:

West Virginia University Health Sciences Center

Department:

West Virginia Clinical & Translational Science Institute

Classification:

Admin

Professor of Medicine
Section of Infectious Diseases

Organization:

West Virginia University School of Medicine

Department:

Medicine

Classification:

Faculty

Associate Vice President for Clinical & Translational Science Director

Organization:

West Virginia University Health Sciences Center

Department:

Administration

Classification:

Admin

1. Hodder SL, Justman J, Hughes JP, Wang J, Haley DF, Adimora AA, Del Rio C, Golin CE, Kuo I, Rompalo A, Soto-Torres L, Mannheimer SB, Johnson-Lewis L, Eshleman SH, El-Sadr WM. HIV acquisition among women from selected areas of the United States: a cohort study. Ann Intern Med. 2013 Jan 1;158(1):10-8. PubMed PMID: 23277896; PubMed Central PMCID: PMC4033695.
2. Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P, Mohapi L, Short W, Crauwels H, Vanveggel S, Boven K. Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. 2012 Aug;13(7):406-15. PubMed PMID: 22416849.
3.  Kulkarni R, Hodder SL, Cao H, Chang S, Miller MD, White KL.  Week 48 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir+Ritonavir+Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES GS-US-236-0128).  HIV Clin Trials, 2017,18:164-173.  PMID 28891788

Honors

1980                   Alpha Omega Alpha, CWRU School of Medicine, Cleveland, OH

1996                   Woman of the Year, Culver Educational Foundation, Culver, IN

1998                   Distinguished Service Award, New Philadelphia High School, New Philadelphia, OH

2003                   President’s Award, Bristol-Myers Squibb Company, Princeton, NJ

2004                   Patient Care Medical Achievement Award, Bristol-Myers Squibb Company, Princeton, NJ

2004                   Innovation Medical Affairs Achievement Award, Bristol-Myers Squibb Company, Princeton, NJ

2010                   Women of Excellence Award, New Jersey Women & AIDS Network, New Brunswick, NJ

2012                   Research Excellence Award, New Jersey Medical School, Newark, NJ

2013                   Faculty of the Year Award, New Jersey Medical School, Newark, NJ

I am a seasoned infectious diseases physician with extensive experience in the area of clinical trials, serving as Principal Investigator (PI) for several important NIH-funded U awards (2UM1AI069419; U54GM104942-02) and protocol chair for a large (>2000 participant) NIH-supported trial in the area of HIV prevention. From 2003-2005, I served as Vice President of Virology Medical Affairs, Bristol-Myers-Squibb, a position in which I was responsible for 118 Phase IIIb/IV trials worldwide.  In 2005, I was recruited to Rutgers University, Newark, New Jersey, to build an HIV program where HIV prevalence was nearly 3% among the African American community, but where (at that time) there was not an active NIH Division of AIDS adult trial site. We successfully competed and were awarded as a site in the AIDS Clinical Trials Group (ACTG) as well as the HIV Prevention Trials Network (both NIH-supported trial networks).  As Protocol Chair for the HIV Prevention Trials Network 064 trial (a multi-site study of HIV incidence and risk behaviors among 2,099 US women), I worked effectively with investigator teams to successfully create and execute this study.  In 2014, I was recruited to direct the West Virginia Clinical and Translational Science Institute (WVCTSI) and serve as PI for the current NIH funded Institutional Development Award (IDeA), Clinical and Translational Research (CTR), which was successfully renewed in 2017. 

Ongoing Research Support

U54 GM104942-02               Hodder (PI)              07/01/17-06/30/22

West Virginia IDEA-CTR       

The goal of this grant is to create research infrastructure that will positively impact health outcomes in West Virginia.    

Role: PI

Completed Research Support

U54 GM104942-01                Hodder (PI)               08/15/12-06/30/17

West Virginia IDEA-CTR

The goal of this grant was to create research infrastructure that would positively impact health outcomes in West Virginia.   

Role: PI

2UM1AI069419                      Hodder (PI)                12/01/13-08/22/14

NIAID

Weill Cornell Medical college-New Jersey Medical School AIDS Clinical Trials Unit.

The goals of this study was to provide HIV treatment and prevention trials to impacted populations in the metro New York area as well as to provide scientific leadership to the AIDS Clinical Trials Group (ACTG) and the HIV Prevention Trials Network (HPTN).

Role: CPI

New Jersey Dept. of Health (DOH)                Hodder (PI)         01/01/12-08/22/14

HIV Counseling, Testing, and Referral Services

The goal of  this program was to expand HIV rapid testing throughout Newark, NJ.

Role: PI

R01 AI110372-01                 Hodder (PI)                     01/01/13-06/01/14

NIAID

Modulation of Innate Immunity and Microbiome by Depo- Provera and its impact on HIV transmission.

The goal of this study was to assess impact of Depo-Provera on immunologic parameters as well as on the microbiome. My role was to create the clinical protocol and to organize participant recruitment.

Role: PI

U01AI069466                     Hodder (PI)                    01/01/07-02/01/14

NIAID

Centers for Innovative Research to Control AIDS (HIV Prevention)

The goals of this project were to provide HIV prevention trials to vulnerable populations in Newark, NJ as well as to provide scientific leadership to the HIV Prevention Trials Network (HPTN).

Role: Consortium PI

5UM1AI069503                  Hodder (PI)                 02/01/07-01/31/14

NIAID

Terri Bairn CPCRA Clinical Trials Unit (AIDS Clinical Trials Group site), National Institutes of Health

The goals of this study were to provide HIV treatment trials to impacted populations in Newark, NJ as well as to provide scientific leadership to the AIDS Clinical Trials Group (ACTG).

Role: PI

GlaxoSmithKline LLC- VIKING           Hodder (PI)           01/01/11-01/01/14

ING112574 A Phase III study to demonstrate the antiviral activity and safety of dolutegravir in HIV-1-infected adult subjects with treatment failure on an integrase inhibitor containing regimen

Trial assessed new integrase inhibitor amongst HIV-infected patients failing 1^st generation integrase inhibitors.

Role: Consortium PI

GSKline- SAILING            Hodder (PI)                     01/01/10-01/01/14

ING111762 A Phase III study to demonstrate the antiviral activity and safety of dolutegravir

Trial assessed a new integrase inhibitor in patients failing current regimens.

Role: Consortium PI

City of Newark, Dept of HHS           Hodder (PI)              01/01/12-01/01/14

Minority AIDS Initiative, Ryan White Part F

Project provided comprehensive gynecological services to HIV-infected women for purposes of improving cervical cancer screening & enhancing indicated colposcopy follow-up.

Role: PI

Gilead Sciences              Hodder (PI)                       01/01/14-01/01/14

A Randomized, Double-Blind Phase 3B Study to Evaluate Safety & Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir vs ritonavir-boosted Atazanavir+ Emtricitabine/Tenofovir in HIV-1 infected Antiretroviral Treatment-Naïve Women

This was the first antiretroviral trial conducted completely amongst women comparing a fixed-dose combination containing a newer integrase inhibitor with a standard protease inhibitor-based regimen. My role was not only that of site-PI but also helped design protocol and was one of the lead investigators for the trial.

Role: Consortium PI

Tibotec Pharmaceuticals             Hodder (PI)                 01/01/11-01/01/14

TMC435-TiDP16-C212 A Phase III Open-Label Study to Evaluate the safety, tolerability and efficacy of TMC435 plus PegIFNa-2a (Pegasys) and ribavirin (Copegus) triple therapy in chronic hepatitis C genotype-1 infected subjects who are co-infected with human immunodeficiency virus type 1 (HIV-1)

Role: Consortium PI

5 H76HA00030                 Hodder (PI)                     01/01/05-01/01/14

HRSA

Early Intervention Services with Respect to HIV Disease

The goal of this program was to identify and connect to care HIV-infected persons.

Role: PI